## ME THERAPEUTICS HOLDINGS INC.

177 Robson Street Vancouver, BC V6B 0N3 Telephone: 236.516.7714

## NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING

## TO THE SHAREHOLDERS:

**NOTICE IS HEREBY GIVEN** that the annual general and special meeting (the "**Meeting**") of shareholders of ME Therapeutics Holdings Inc. (the "**Company**") will be held at the offices of Clark Wilson LLP, 900 – 885 West Georgia Street, Vancouver, BC, V6C 3H1 on Thursday, March 14, 2024, at the hour of 10:00 a.m. (Vancouver time) for the following purposes:

- (1) to receive the audited financial statements of the Company for the fiscal year ended August 31, 2023, and the accompanying report of the auditors;
- (2) to set the number of directors of the Company for the ensuing year at four (4);
- (3) to elect Dr. Salim Zulifkar Dhanji, Dr. John Priatel, Dr. Kenneth Harder and Karim Nanji as directors of the Company;
- (4) to appoint Davidson & Company LLP as the auditors of the Company for the fiscal year ending August 31, 2024 and to authorize the directors of the Company to fix the remuneration to be paid to the auditors for the fiscal year ending August 31, 2024;
- (5) to consider and, if thought fit, to pass an ordinary resolution to ratify, confirm and re-approve the Company's Stock Option Plan, as described in the accompanying information circular (the "Information Circular"); and
- (6) to transact such further or other business as may properly come before the Meeting and any adjournment or postponement thereof.

The accompanying Information Circular provides additional information relating to the matters to be dealt with at the Meeting and is supplemental to, and expressly made a part of, this notice of Meeting (the "Notice of Meeting").

The board of directors of the Company has fixed February 5, 2024 as the record date for the determination of shareholders entitled to notice of and to vote at the Meeting and at any adjournment or postponement thereof. Each registered shareholder at the close of business on that date is entitled to such notice and to vote at the Meeting in the circumstances set out in the accompanying Information Circular.

If you are a registered shareholder of the Company and unable to attend the Meeting in person, please vote by proxy by following the instructions provided in the form of proxy at least 48 hours (excluding Saturdays, Sundays and holidays recognized in the Province of British Columbia) before the time and date of the Meeting or any adjournment or postponement thereof.

In view of COVID-19, the Company asks that, in considering whether to attend the Meeting in person, shareholders follow the instructions of the Public Health Agency of Canada (<a href="https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html">https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html</a>). The Company encourages Shareholders not to attend the Meeting in person if experiencing any of the described COVID-19 symptoms of fever, cough or difficulty breathing. The Company may take additional precautionary measures in relation to the Meeting in response to

further developments in the COVID-19 outbreak. As always, the Company encourages Shareholders to vote on the matters prior to the Meeting by proxy.

If you are a non-registered shareholder of the Company and received this Notice of Meeting and accompanying materials through a broker, a financial institution, a participant, or a trustee or administrator of a retirement savings plan, retirement income fund, education savings plan or other similar savings or investment plan registered under the Income Tax Act (Canada), or a nominee of any of the foregoing that holds your securities on your behalf (each, an "Intermediary"), please complete and return the materials in accordance with the instructions provided to you by your Intermediary.

**DATED** at Vancouver, British Columbia, this 9<sup>th</sup> day of February, 2024.

By Order of the Board of Directors of

ME THERAPEUTICS HOLDINGS INC.

<u>"Salim Zulifkar Dhanji"</u>

Dr. Salim Zulifkar Dhanji Chief Executive Officer and Director

PLEASE VOTE. YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU EXPECT TO ATTEND THE MEETING, PLEASE COMPLETE, SIGN AND DATE THE ENCLOSED FORM OF PROXY AND PROMPTLY RETURN IT IN THE ENVELOPE PROVIDED.